Samsung Bioepis Joins Biosimilar Lucentis Fray As It Unveils Phase III Plans
Executive Summary
Samsung Bioepis has said it is preparing a Phase III trial with a proposed ranibizumab biosimilar, joining a number of players developing biosimilar versions of the ophthalmic use drug, which loses its first major patents in the next few years.
You may also be interested in...
Lucentis Biosimilar To Be Sold To Emerging Markets By Xbrane Biopharma
Stockholm-based Xbrane Biopharma plans to be the first to sell a biosimilar version of Lucentis in Iran as part of its strategy to leverage patent gaps in emerging markets for high-priced drugs.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.